A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
Conditions
- Alzheimer's Disease
- Huntington's Disease
Interventions
- DRUG: Dimebon
- DRUG: Dimebon
Sponsor
Pfizer
Collaborators